Patryk Cyran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Patryk Cyran has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Agata Porwolik
Professor Zbigniew Religa Student Scientific Association at the Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Jordana 19, 41-808 Zabrze, Poland
4 shared publications - Hanna Porwolik
Medical University of Silesia, Katowice, Poland
4 shared publications - Magdalena Bodera
Professor Zbigniew Religa Student Scientific Association at the Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland
4 shared publications - Radosław Szydłowski
Medical University of Silesia, Katowice, Poland
4 shared publications - Anna Kaźmierska
Medical University of Silesia, Katowice, Poland
2 shared publications - Dominik Bylica
Zespół Szpitali Miejskich w Chorzowie, Chorzów, Poland
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
IODINE SUPPLEMENTATION IN CHILDHOOD: PREVENTING THYROID DISORDERS IN THE ERA OF PRECISION MEDICINE
Iodine deficiency disorders (IDDs) are a group of conditions that have been identified as one of the most preventable but persisting important causes of irreversible neuro-cognitive impairment among paediatric populations across the world (Bertinato, 2021; Feei & Brough, 2025; Zimmermann & Andersson, 2021). Existing universal supplementation programmes are showing to be inadequate as they do not accommodate the new regional deficiencies and the concomitant risk of iodine excess (Kalarani & Veerabathiran, 2022; Seetharaman et al., 2024). This paper proposes a paradigm shift in paediatric endocrinology to precision medicine, in which the iodine interventions are tailored to each child. Wearable biosensors, which continuously monitor physiological and biochemical parameters, complex mobile-health applications which can track dietary intake in real-time, support adherence, and education, as well as comprehensive telehealth platforms which allow remote care (Fernández-Luque et al., 2021; Foster et al., 2022; Kim et al., 2023; Magsayo & Khatami, 2025; Majeed‐Ariss et al., 2015; Mercuri et al., 2021; Rashid, 2024; Zhou et al., 2024). Integration of advanced biomarkers and multi-omics data (genomics, proteomics, metabolomics and microbiomics) - integrated with AI/ML algorithms - will help to dynamically predict risk, implement early intervention strategies and design protocols for the supplementation of these individuals (Bidlingmaier et al., 2022; Dhanka et al., 2025; Giorgini et al., 2023; Lu et al., 2025; Mehta et al., 2025). By combining technology with personalised care, this strategy promises to optimise iodine nutrition, protect neurodevelopment and enhance the long term health outcomes of all children (Delange, 2007; Milanesi & Brent, 2016; Untoro et al., 2007).
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessIODINE SUPPLEMENTATION IN CHILDHOOD: PREVENTING THYROID DISORDERS IN THE ERA OF PRECISION MEDICINE
Iodine deficiency disorders (IDDs) are a group of conditions that have been identified as one of the most preventable but persisting important causes of irreversible neuro-cognitive impairment among paediatric populations across the world (Bertinato, 2021; Feei & Brough, 2025; Zimmermann & Andersson, 2021). Existing universal supplementation programmes are showing to be inadequate as they do not accommodate the new regional deficiencies and the concomitant risk of iodine excess (Kalarani & Veerabathiran, 2022; Seetharaman et al., 2024). This paper proposes a paradigm shift in paediatric endocrinology to precision medicine, in which the iodine interventions are tailored to each child. Wearable biosensors, which continuously monitor physiological and biochemical parameters, complex mobile-health applications which can track dietary intake in real-time, support adherence, and education, as well as comprehensive telehealth platforms which allow remote care (Fernández-Luque et al., 2021; Foster et al., 2022; Kim et al., 2023; Magsayo & Khatami, 2025; Majeed‐Ariss et al., 2015; Mercuri et al., 2021; Rashid, 2024; Zhou et al., 2024). Integration of advanced biomarkers and multi-omics data (genomics, proteomics, metabolomics and microbiomics) - integrated with AI/ML algorithms - will help to dynamically predict risk, implement early intervention strategies and design protocols for the supplementation of these individuals (Bidlingmaier et al., 2022; Dhanka et al., 2025; Giorgini et al., 2023; Lu et al., 2025; Mehta et al., 2025). By combining technology with personalised care, this strategy promises to optimise iodine nutrition, protect neurodevelopment and enhance the long term health outcomes of all children (Delange, 2007; Milanesi & Brent, 2016; Untoro et al., 2007).
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
COMPLICATIONS OF TRANSCATHETER AORTIC VALVE IMPLANTATION
Transcatheter aortic valve implantation (TAVI) has become an established and widely adopted treatment for patients with severe aortic stenosis across all surgical risk categories. Continuous technological progress, refinements in device design, and increasing operator experience have substantially improved procedural safety and expanded indications from inoperable and high-risk patients to those at intermediate and low surgical risk. Nevertheless, despite these advancements, TAVI remains associated with a broad spectrum of complications that may adversely affect both short- and long-term outcomes. This review provides a comprehensive overview of the most clinically significant complications following TAVI, including vascular, valvular, neurological, renal, bleeding, infectious, and conduction-related events. Particular attention is given to the underlying pathophysiological mechanisms, patient- and procedure-related risk factors, and contemporary prevention and management strategies. Although the incidence of major vascular complications has decreased with the introduction of lower-profile delivery systems, these events remain clinically relevant, particularly in elderly patients and those with complex vascular anatomy. Conduction disturbances frequently require permanent pacemaker implantation, while stroke and silent cerebral embolization continue to represent major neurological concerns. Acute kidney injury and major bleeding significantly contribute to morbidity and mortality, and prosthetic valve endocarditis, although rare, carries a particularly poor prognosis. A thorough understanding of the mechanisms and predictors of post-TAVI complications is essential for optimizing patient selection, procedural planning, and post-procedural management. Ongoing innovations in device technology and procedural techniques remain fundamental to further improving clinical outcomes and minimizing procedural risk.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessCOMPLICATIONS OF TRANSCATHETER AORTIC VALVE IMPLANTATION
Transcatheter aortic valve implantation (TAVI) has become an established and widely adopted treatment for patients with severe aortic stenosis across all surgical risk categories. Continuous technological progress, refinements in device design, and increasing operator experience have substantially improved procedural safety and expanded indications from inoperable and high-risk patients to those at intermediate and low surgical risk. Nevertheless, despite these advancements, TAVI remains associated with a broad spectrum of complications that may adversely affect both short- and long-term outcomes. This review provides a comprehensive overview of the most clinically significant complications following TAVI, including vascular, valvular, neurological, renal, bleeding, infectious, and conduction-related events. Particular attention is given to the underlying pathophysiological mechanisms, patient- and procedure-related risk factors, and contemporary prevention and management strategies. Although the incidence of major vascular complications has decreased with the introduction of lower-profile delivery systems, these events remain clinically relevant, particularly in elderly patients and those with complex vascular anatomy. Conduction disturbances frequently require permanent pacemaker implantation, while stroke and silent cerebral embolization continue to represent major neurological concerns. Acute kidney injury and major bleeding significantly contribute to morbidity and mortality, and prosthetic valve endocarditis, although rare, carries a particularly poor prognosis. A thorough understanding of the mechanisms and predictors of post-TAVI complications is essential for optimizing patient selection, procedural planning, and post-procedural management. Ongoing innovations in device technology and procedural techniques remain fundamental to further improving clinical outcomes and minimizing procedural risk.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
MODERN GLP-1 BASED PHARMACOTHERAPY FOR SEVERE ADOLESCENT OBESITY: CLINICAL PROMISE, SAFETY CONCERNS, AND ETHICAL CHALLENGES
Childhood obesity is an emerging worldwide health crisis, which has far-reaching harmful impacts on the health and development of affected adolescents (Hesketh et al., 2024; Li et al., 2024; Marcus et al., 2022). Innovative therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown great promise as pharmacological intervention, with substantive clinical benefit to the population. This review provides a detailed synthesis of GLP-1RAs from the perspectives of their pharmacological mechanisms, clinical potential in adolescents, safety profiles and associated ethical and social considerations. The pharmacological rationale for GLP-1RAs is due to their ability to mimic the effect of endogenous GLP-1, a hormone which plays an important role in maintaining glucose homeostasis and in regulating appetite (Moiz et al., 2025; Muzurović et al., 2022). These agents promote glucose-dependent insulin secretion, reduce glucagon release and also slow gastric emptying, thereby attenuating glycaemic excursions after a meal and promoting satiety (Alharbi, 2025; Drucker, 2021; Shah & Vella, 2014). Importantly, GLP-1RAs also activate receptors in the central nervous system to reduce hunger and food intake, which result in weight loss of significant and sustained magnitude (Dailey & Moran, 2013; Hayes, 2012; Moiz et al., 2025). This multifaceted mechanism is the basis of their efficacy to treat both type 2 diabetes and obesity. Within the adolescent age group, GLP-1RAs have shown significant clinical potential especially with liraglutide and semaglutide.Liraglutide, approved for people aged 12-17 years, has led to better body mass index (BMI) z-score and clinically significant reduction in weight compared with placebo (Berman et al., 2023; Jensterle & Janež, 2021). Semaglutide, which is approved for adolescents 12+ years, continues to push the efficacy bar and confirmatory trials have reported mean BMI reductions of over 16% with a high prevalence of participants achieving significant weight loss (Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Beyond reducing weight, GLP-1RAs improve key metabolic markers - triglycerides, total cholesterol, HbA1c and systolic blood pressure - which reduces the risk of cardiovascular and type 2 diabetes in the long term (Silvia et al., 2021; Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Moreover, these medications improve weight-related quality of life, especially the physical comfort, which addresses the psychological burden of obesity in youth (Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Despite their efficacy, GLP-1RAs are a unique category of pharmacologic agents with regard to safety profile that requires close scrutiny. Frequently encountered adverse events are gastrointestinal in nature - nausea, vomiting, diarrhoea and constipation - generally being mild, transient and amenable to dose titration (Santos & Castro, 2025; Silvia et al., 2021). More serious issues include proven risks of cholelithiasis and acute pancreatitis, as seen in some trials (Weghuber et al., 2022; Woronow et al., 2022). A black box warning (defined by FDA) is used to alert clinicians to the potential risk of thyroid C-cells tumours, such as medullary thyroid carcinoma, based on rodent studies, and therefore require contraindication in certain clinical situations (Bezin et al., 2022; Kelly & Sipos, 2024; Pasternak et al., 2024).Long-term data on the effect of GLP-1RA on adolescent growth, pubertal development and neuropsychiatric outcomes (including suicidal ideation) are still sparse and the need for continued, rigorous surveillance (Bartkoski et al., 2025; Cooper et al., 2023). Ethical and societal considerations are very important when incorporating GLP-1RAs into the care of adolescents. Challenges include the need for truly informed consent, and respect for adolescent autonomy, in particular because of the chronic nature of therapy (Turhal & Bağlam, 2025; Viner et al., 2020). Dramatic increases in cost and poor insurance coverage create important equity issues, which may serve to exacerbate health disparities (Berman et al., 2023; Wright et al., 2023). Societal stigma against obesity and the potential for reinforcing a "weight-normative" paradigm or misuse for cosmetic purposes also need to be watched out for (Button et al., 2025; Cominato et al., 2021; Floegel‐Shetty, 2023). A holistic approach that goes beyond simply reducing weight to include but is not limited to metabolic health, psychological wellbeing, and quality of life is crucial to ethical and effective practice. In conclusion, GLP-1RAs have been shown to be a transformational approach in the management of severe obesity in adolescents, but their introduction into the clinic will need to be accompanied by a commitment to long-term safety studies and equitable and patient-centred care.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessMODERN GLP-1 BASED PHARMACOTHERAPY FOR SEVERE ADOLESCENT OBESITY: CLINICAL PROMISE, SAFETY CONCERNS, AND ETHICAL CHALLENGES
Childhood obesity is an emerging worldwide health crisis, which has far-reaching harmful impacts on the health and development of affected adolescents (Hesketh et al., 2024; Li et al., 2024; Marcus et al., 2022). Innovative therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown great promise as pharmacological intervention, with substantive clinical benefit to the population. This review provides a detailed synthesis of GLP-1RAs from the perspectives of their pharmacological mechanisms, clinical potential in adolescents, safety profiles and associated ethical and social considerations. The pharmacological rationale for GLP-1RAs is due to their ability to mimic the effect of endogenous GLP-1, a hormone which plays an important role in maintaining glucose homeostasis and in regulating appetite (Moiz et al., 2025; Muzurović et al., 2022). These agents promote glucose-dependent insulin secretion, reduce glucagon release and also slow gastric emptying, thereby attenuating glycaemic excursions after a meal and promoting satiety (Alharbi, 2025; Drucker, 2021; Shah & Vella, 2014). Importantly, GLP-1RAs also activate receptors in the central nervous system to reduce hunger and food intake, which result in weight loss of significant and sustained magnitude (Dailey & Moran, 2013; Hayes, 2012; Moiz et al., 2025). This multifaceted mechanism is the basis of their efficacy to treat both type 2 diabetes and obesity. Within the adolescent age group, GLP-1RAs have shown significant clinical potential especially with liraglutide and semaglutide.Liraglutide, approved for people aged 12-17 years, has led to better body mass index (BMI) z-score and clinically significant reduction in weight compared with placebo (Berman et al., 2023; Jensterle & Janež, 2021). Semaglutide, which is approved for adolescents 12+ years, continues to push the efficacy bar and confirmatory trials have reported mean BMI reductions of over 16% with a high prevalence of participants achieving significant weight loss (Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Beyond reducing weight, GLP-1RAs improve key metabolic markers - triglycerides, total cholesterol, HbA1c and systolic blood pressure - which reduces the risk of cardiovascular and type 2 diabetes in the long term (Silvia et al., 2021; Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Moreover, these medications improve weight-related quality of life, especially the physical comfort, which addresses the psychological burden of obesity in youth (Weghuber, Barrett, et al., 2023; Weghuber, Kelly, et al., 2023). Despite their efficacy, GLP-1RAs are a unique category of pharmacologic agents with regard to safety profile that requires close scrutiny. Frequently encountered adverse events are gastrointestinal in nature - nausea, vomiting, diarrhoea and constipation - generally being mild, transient and amenable to dose titration (Santos & Castro, 2025; Silvia et al., 2021). More serious issues include proven risks of cholelithiasis and acute pancreatitis, as seen in some trials (Weghuber et al., 2022; Woronow et al., 2022). A black box warning (defined by FDA) is used to alert clinicians to the potential risk of thyroid C-cells tumours, such as medullary thyroid carcinoma, based on rodent studies, and therefore require contraindication in certain clinical situations (Bezin et al., 2022; Kelly & Sipos, 2024; Pasternak et al., 2024).Long-term data on the effect of GLP-1RA on adolescent growth, pubertal development and neuropsychiatric outcomes (including suicidal ideation) are still sparse and the need for continued, rigorous surveillance (Bartkoski et al., 2025; Cooper et al., 2023). Ethical and societal considerations are very important when incorporating GLP-1RAs into the care of adolescents. Challenges include the need for truly informed consent, and respect for adolescent autonomy, in particular because of the chronic nature of therapy (Turhal & Bağlam, 2025; Viner et al., 2020). Dramatic increases in cost and poor insurance coverage create important equity issues, which may serve to exacerbate health disparities (Berman et al., 2023; Wright et al., 2023). Societal stigma against obesity and the potential for reinforcing a "weight-normative" paradigm or misuse for cosmetic purposes also need to be watched out for (Button et al., 2025; Cominato et al., 2021; Floegel‐Shetty, 2023). A holistic approach that goes beyond simply reducing weight to include but is not limited to metabolic health, psychological wellbeing, and quality of life is crucial to ethical and effective practice. In conclusion, GLP-1RAs have been shown to be a transformational approach in the management of severe obesity in adolescents, but their introduction into the clinic will need to be accompanied by a commitment to long-term safety studies and equitable and patient-centred care.
- Open Access
- 4 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
CRISPR-Cas9 GENE EDITING: MECHANISMS, CLINICAL APPLICATIONS, AND FUTURE PERSPECTIVES
The system of gene editing known as the CRISPR-Cas9 system has revolutionized the field of gene editing and provides a platform that allows for the modification of genetic sequences with precision and efficiency, having implications for both the basic research of science and for treatments. Its mechanism, which is derived from bacterial adaptive immunity, consists of a guide RNA that leads to specific epigenetic DNA sites a nuclease named Cas, to target it for cleavage; this permits gene correction, inactivation, or insertion. The clinical potential of this technology is enormous with applications ranging from hereditary diseases, oncology, and infectious diseases. Of note too, the approvals from the FDA for therapies targeted at the treatment of sickle cell anemia and beta thalassemia speaks volumes to its transformative effect on what was previously in-treatable conditions. In oncology, the technologies are increasing immunotherapies by engineering T-cells and interfering with immune checkpoints, but also working on viral genomes (e.g. HIV, HBV) and destroying antibiotic-resistance genes in bacteria. However, there are still major challenges such as off-target effects, in vivo delivery efficiency and possible immunogenicity of Cas proteins. Future advancements are dedicated to refine the use of the CRP systems using advanced variants such as base and prime editors, and to extend the toolkit by Cas12 and Cas13 for RNA/DNA targeting, as well as devising innovative delivery systems for overcoming the biological barriers. Ethical, regulatory, and societal considerations are paramount in the continued promotion and progressive growth of this technology.
- 4 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessCRISPR-Cas9 GENE EDITING: MECHANISMS, CLINICAL APPLICATIONS, AND FUTURE PERSPECTIVES
The system of gene editing known as the CRISPR-Cas9 system has revolutionized the field of gene editing and provides a platform that allows for the modification of genetic sequences with precision and efficiency, having implications for both the basic research of science and for treatments. Its mechanism, which is derived from bacterial adaptive immunity, consists of a guide RNA that leads to specific epigenetic DNA sites a nuclease named Cas, to target it for cleavage; this permits gene correction, inactivation, or insertion. The clinical potential of this technology is enormous with applications ranging from hereditary diseases, oncology, and infectious diseases. Of note too, the approvals from the FDA for therapies targeted at the treatment of sickle cell anemia and beta thalassemia speaks volumes to its transformative effect on what was previously in-treatable conditions. In oncology, the technologies are increasing immunotherapies by engineering T-cells and interfering with immune checkpoints, but also working on viral genomes (e.g. HIV, HBV) and destroying antibiotic-resistance genes in bacteria. However, there are still major challenges such as off-target effects, in vivo delivery efficiency and possible immunogenicity of Cas proteins. Future advancements are dedicated to refine the use of the CRP systems using advanced variants such as base and prime editors, and to extend the toolkit by Cas12 and Cas13 for RNA/DNA targeting, as well as devising innovative delivery systems for overcoming the biological barriers. Ethical, regulatory, and societal considerations are paramount in the continued promotion and progressive growth of this technology.